

AMENDMENT TO THE SPECIFICATION

IN THE ABSTRACT OF THE DISCLOSURE:

Please amend the abstract to read as follows.:

This invention relates to detection of specific extracellular nucleic acid in human or animal blood plasma or serum ~~fractions of human or animal blood~~ associated with ~~neoplastic, pre-malignant or proliferative~~ disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to ~~these~~ methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the blood plasma or serum ~~fraction of blood by using DNA extraction with or without enrichment for mutant DNA~~. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of ~~benign, premalignant, or malignant neoplasms~~ neoplasia in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. ~~The invention permits the detection of extracellular, tumor-associated nucleic acid in the blood serum or plasma of humans or other animals recognized as having a neoplastic, pre-malignant or proliferative disease or in individuals without any prior history or diagnosis of neoplastic, pre-malignant or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such as oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic, pre-malignant or proliferative disease. The invention thereby provides methods for early identification of colorectal, pancreatic, lung, breast, bladder, ovarian, lymphoma and other malignancies carrying tumor-related mutations of DNA and methods for monitoring cancer and other neoplastic disorders in humans and other animals.~~